Full name
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT Number
NCT06317285
Geography
US
Non-US
Locations
Argentina, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Primary Endpoints
Absolute Change from Baseline in Forced Vital Capacity (FVC) in milliliters (mL) at Week 26
External Link
https://clinicaltrials.gov/study/NCT06317285
Order
1
Disease
Version
Phase
2
Status
Recruiting